Lawrenceville, NJ, United States of America

Rex A Parker

This inventor holds 18 USPTO granted patents, plus 1 CIPO patent and 4 EPO patents, primarily in Fibronectin Binding Proteins. Top assignees: Bristol-Myers Squibb Compnay, Harvard College, Bristol Meyers Squibb Company. Active years: 1993-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rex A Parker. Retrieved from https://idiyas.com/inventor/rex-a-parker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18

% Patents Active = 88.9

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 5.7

ph-index = 9

Forward Citations = 281(Granted Patents)

Location History:

Branford, CT (US) (1993 - 1994)
Lawrenceville, NJ (US) (1996)
Titusville, NJ (US) (2006 - 2024)

Company Filing History:

17 out of 3,745

Bristol-Myers Squibb Compnay

Bristol Meyers Squibb Company

patents

where one patent can have more than one assignee

Years Active: 1993-2026

Loading Chart...

Areas of Expertise:

Fibronectin

PCSK9

Atherosclerosis

Diabetes

Polynucleotides

Serum Albumin

Inhibitors

Hyperlipidemia

Hypercholesterolemia

Anti-Atherogenic

Scaffold Domain Proteins

Fatty Acid Binding Proteins

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12534511 - SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS (2026-01-27),

2. 11858979 - Fibronectin based scaffold domain proteins that bind PCSK9 (2024-01-02),

3. 11203630 - Serum albumin-binding fibronectin type III domains (2021-12-21),

4. 10947297 - Fibronectin based scaffold domain proteins that bind PCSK9 (2021-03-16),

5. 10442851 - Serum albumin-binding fibronectin type III domains (2019-10-15),

6. 9856309 - Fibronectin based scaffold domain proteins that bind PCSK9 (2018-01-02),

7. 9234027 - Fibronectin based scaffold domain proteins that bind PCSK9 (2016-01-12),

8. 8420098 - Fibronectin based scaffold domain proteins that bind to PCSK9 (2013-04-16),

9. 8354264 - Polynucleotides encoding novel PCSK9 variants (2013-01-15),

10. 8105804 - Polynucleotides encoding novel PCSK9 variants (2012-01-31),

11. 7846706 - PCSK9 polypeptides (2010-12-07),

12. 7572618 - Polynucleotides encoding novel PCSK9 variants (2009-08-11),

13. 7390824 - Method for treating diabetes employing an aP2 inhibitor and combination (2008-06-24),

14. 7358254 - Method for treating atherosclerosis employing an aP2 inhibitor and combination (2008-04-15),

15. 6984645 - Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein (2006-01-10),

Title: **Rex A Parker: Innovator in Protein Therapeutics**

Introduction

Rex A Parker is a distinguished inventor based in Lawrenceville, NJ, who has made significant contributions to the field of protein therapeutics. With an impressive portfolio of 17 patents, he is recognized for his pioneering work in developing innovative proteins aimed at treating various cholesterol-related diseases.

Latest Patents

Among Rex A Parker's latest patents is the invention of fibronectin-based scaffold domain proteins that bind PCSK9. This groundbreaking invention addresses critical health issues by providing therapeutic applications for conditions like atherosclerosis and hypercholesterolemia. Furthermore, it encompasses cells that incorporate these proteins, polynucleotides that encode them, and vectors containing the relevant polynucleotides. Another notable patent involves serum albumin-binding fibronectin type III domains. This invention focuses on polypeptides that include the tenth fibronectin type III domains (Fn3) with unique substitutions, enabling them to bind to serum albumin. Additionally, it details fusion molecules that consist of a serum albumin-binding Fn3 joined to a heterologous protein, intended for diagnostic and therapeutic uses.

Career Highlights

Rex A Parker's professional journey includes notable affiliations with Bristol-Myers Squibb Company and Harvard College. His work in these prestigious organizations has allowed him to refine his expertise and focus on innovations that drive advancements in therapeutic strategies.

Collaborations

Throughout his career, Rex has collaborated with talented individuals such as Bowman Miao and Ray Camphausen. These partnerships have further enriched the development and impact of his inventions, fostering an environment of innovation and collaborative problem-solving.

Conclusion

Rex A Parker stands out as a prominent figure in the realm of protein therapeutics, with a strong patent portfolio that underscores his commitment to addressing significant health challenges. His contributions not only enhance the scientific community but also pave the way for innovative solutions that can positively affect the lives of many individuals suffering from cholesterol-related conditions.

Profile summary based on public USPTO records.